Loading clinical trials...
Loading clinical trials...
A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic Chemotherapy
Conditions
Interventions
Fosaprepitant Dimeglumine
5-HT3 antagonist
+1 more
Locations
26
United States
Phoenix Childrens Hospital ( Site 1101)
Phoenix, Arizona, United States
Southern California Permanente Medical Group ( Site 1104)
Los Angeles, California, United States
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 1106)
Chicago, Illinois, United States
Children's Hospitals and Clinics of Minnesota ( Site 1109)
Minneapolis, Minnesota, United States
St. Jude Children's Research Hospital ( Site 1111)
Memphis, Tennessee, United States
Athens Childrens Hospital Aglaia Kyriakou ( Site 0101)
Athens, Attica, Greece
Start Date
September 9, 2019
Primary Completion Date
February 11, 2021
Completion Date
February 11, 2021
Last Updated
January 16, 2025
NCT05838638
NCT02106494
NCT01937156
NCT04472143
NCT03245918
NCT02909478
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions